Tirzepatide acts on two gut hormones and is sold as Mounjaro for diabetes and Zepbound for obesity. Lilly now also sells a pill, Foundayo, against Novo Nordisk's drugs.
The company · 2 · What exactly does it sell?
One molecule is two thirds of sales
Each $1 of sales, second quarter of 2026
65%15%11%6%3%
Mounjaro and ZepboundOther diabetes and heartCancerImmune diseasesBrain and other
Everything else Lilly sells together is about a third.
The company · 3 · How does it make money?
Insurers and governments pay for weekly shots
$24.4Bsales last quarter
83.9%kept per $1 after making it
$16.71of tirzepatide a quarter per person
Insurers and governments decide how many patients are covered and at what price.
Is it a good business? · 4 · What gives it an edge?
A strong patent, with a date on it
13 May 2036
US patent end for tirzepatide
2037 and 2040
Europe and Japan
+48%
Lilly's growth, Novo flat to down
Novo has conceded both US prescription leads to Lilly.
Insurers can switch all their patients at once, as CVS showed.
Is it a good business? · 6 · What does its record show?
Sales more than doubled, profit widened
Sales, $B
28.3
28.5
34.1
45.0
65.2
Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Sales$28.3B → $65.2Bsales, 2021 to 2025
Kept74% → 83%kept per $1 after making it
Profit20% → 32%net profit per $1
Factories are bought ahead of volume, so capital spending per dollar more than doubled.
Is it a good business? · 7 · How much room is there to grow?
The limit is who pays, not patients
890 millionadults with obesity, WHO, 2022
40.3%the US obesity rate
Patients are plentiful; insurers and governments decide how many are treated and at what price.
Is it a good business? · 8 · Who is in charge?
A long-serving chief and research head
2017David Ricks became chief executive
2018Daniel Skovronsky took over research
Lucas Montarcethe third finance chief since 2021
Insiders own almost none of the company, and the finance seat keeps changing.
The story right now · 9 · Why are obesity drugs so big?
Weekly shots that cut weight sharply
+53%Lilly's volume growth
−15%lower prices
$91B to $92B2026 sales forecast
Drugs that mimic gut hormones help people lose weight. Patients are plentiful, so the question is how many of them insurers and governments will pay for.
The story right now · 10 · Can volume outrun price cuts?
More patients at lower prices
Prices cut to widen access15% lower.
Many more patientsVolume +53%.
Sales still jump+39%.
Coverage can endMedicare has a date.
Volume outran price cuts this year, but Medicare coverage has an end date and a rival won the pill's first year.
The story right now · 11 · What changed lately?
Sales up 39% and the forecast raised again
$24.4Bsales in the third quarter
$184Mof Foundayo, the pill
About $900Mof sales was one-off
2forecast raises this year
Strong quarter
Buyers paid no more for each dollar of sales than a year before, so the share rise was earned.
The story right now · 12 · What is everyone arguing about?
Has Lilly won obesity for good?
Many investors think
Lilly has won obesity and keeps compounding
We think
A rival won the pill, and coverage has an expiry date
The market has twice sold these shares hard on one setback and been wrong both times.
The price and our view · 13 · What is a share worth?
Cheaper than its history, still above our value
$943what we think a share is worth · the last close is of that
$943our value
Attractive below $754
Neutral
Unattractive above $1,131
$433gloomy: growth halves, less kept per $1
$943our estimate: experts' path, then slowing
$1,326sunny: growth beats the forecast by a quarter
Value per share in three futures. None is a prediction of the share price.
We estimate what a share is worth from the cash the business should earn over many years. Our rule: buy only when the price is at least a fifth below our estimate, as a cushion for being wrong.
The price and our view · 14 · What if it all works?
As a bet on its new drugs, it is fragile
Priced for successthe kind of bet this is
0.8×if it works
73%kept if it fails
Multiples of the company's value when the bet was last struck, 9 Nov 2026.
If the pill and retatrutide succeed, the shares are worth about what they cost, so the price already pays for success.
The price and our view · 15 · How could we be wrong?
One molecule carries the company
A generic challengeBiggest
On the one molecule.
Coverage with an end dateShowing now
Medicare.
Novo's pillWatch
Leads its first year.
Prices insurers payUnknown
Not disclosed.
Insurers can switch all their patients at once, as CVS showed.
The price and our view · 16 · How will we know?
February tests 2027 growth
Foundayo gains on Novo's pillGood sign
Volume keeps outrunning price cutsGood sign
Another insurer drops ZepboundBad sign
FEB 202712
Fourth-quarter and full-year 2026 results, 12 February. Companies report every three months; each report is a test of the story.
Our view also changes on price alone: if the shares fall to within a fifth of our estimate, we move to Neutral.
The price and our view · 17 · So, what do we think?
The obesity leader, resting on one molecule
$943our value
Attractive below $754
Neutral
Unattractive above $1,131
UnattractiveMedium conviction
Mounjaro and Zepbound lead the obesity-drug market and sales grow very fast. But about two thirds of sales come from one molecule, Medicare coverage has an end date, and the price sits above even our sunny future.
↑ ↓ to move · C for contents
What it does
More about the company
Who it is
Lilly is a drug maker, and today mostly one drug. Tirzepatide is a weekly injection that acts on two gut hormones at once, sold as Mounjaro for type 2 diabetes and, identically, as Zepbound for obesity. In August the FDA added heart protection to Mounjaro's label.
A patient's alternatives are diet, surgery, or Novo Nordisk's rival drugs, Wegovy and Ozempic. Lilly now sells a pill as well, Foundayo, which booked its first $98M in the June quarter.
How it makes money
Lilly sells to three big wholesalers, each 16% to 24% of revenue, who resell against prescriptions. It keeps far less than the list price: at the end of June it owed $21.12B in rebates and discounts to insurers and governments. And many patients pay themselves: about 45% of Zepbound prescriptions, at $245 to $449 a month.
Growth and profit
What growth costs
Growing has made Lilly more profitable: making, researching and selling each cost less per dollar of sales than four years ago. The cost that grows faster than sales is factories, built ahead of demand, and the research the company buys in rather than does itself sits on its own line.
Its record
The numbers
Is it growing?Fast
Sales grew 45% in the year to Dec 2025, faster than the 32% in the year before.
Is it profitable?Strong
It keeps 32% of sales as profit, up from 22% in the year to Dec 2022.
What does it keep on each sale?Rich
It keeps 83¢ of each sales dollar after making what it sells, and spends 20¢ of it on research, its biggest running cost.
Does it earn good returns?Strong
Shareholders' money earned 101% a year, up from 76% in the year to Dec 2021.
Is it making cash?Solid
It turned 14% of sales into free cash, $8.97B over the year.
Is the balance sheet safe?Heavy debt
It owes $35.2B more than the cash it holds, about 2.1 years of the cash its operations bring in.
Are shares being diluted?Stable
The share count fell 1.4% in 4.0 years, and pay in shares costs 1.0% of sales.
Why it wins
The evidence
The protection is a patent the regulator itself publishes: nobody may sell tirzepatide in America until 13 May 2036, and Lilly's filing gives 2037 in Europe and 2040 in Japan. That is strong, and it is dated.
Its effect shows in the rival's own words. Novo Nordisk's annual report concedes it lost both American prescription leads during 2025, and Novo now forecasts its 2026 sales flat to down 6% while Lilly grows 48%.
Who could beat it
The rivals in full
Novo is fighting back. It launched its obesity pill in January, calls it the strongest launch of its kind, and still leads that market; Lilly's pill had over 30% of new American pill patients by 14 September. Insurers can switch all their patients at once: CVS Caremark dropped Zepbound from July 2025 until this October. And Pfizer has bought its way in.
Each rival
Novo Nordisk (semaglutide - Wegovy injection, Wegovy HD and the Wegovy pill)NVO
The prescriber writes semaglutide instead of tirzepatide for the same patient and the same indication - the one substitution that is complete rather than partial, and in orals it is currently the default.
CVS Caremark and the other pharmacy benefit managers, as the channel that choosesCVS
Not the molecule but the patient's access to it: a formulary manager substitutes the rival for the whole book at once, without any prescriber changing their mind.
Compounding pharmacies and illicit sellers of unapproved copiesnot listed
The patient stops buying an approved medicine at a payer-negotiated price and buys a copy of the same molecule at a cash price - now including retatrutide, which has no approval at all.
Pfizer (Metsera, and the YaoPharma and 3SBio in-licensing)PFE
A third large manufacturer offers the prescriber an incretin of its own, turning a duopoly into a three-way market and taking the pricing with it.
Generic manufacturers, from 2036 - and the class's first challenges are already filed against the rivalnot listed
Everything. On expiry the same molecule is sold by anyone, and a branded price becomes a generic one.
The patient who wants a pill takes Novo's, launched three months before Foundayo and still the larger seller of the two.
How big it could get
The market and who has signed
The market
The World Health Organization counted 890 million adults living with obesity in 2022, 16% of all adults. In America the rate is 40.3%. Lilly's tirzepatide sales come to $16.71 a quarter for each of those 890 million people, so the limit is not patients but who will pay.
Who runs it
Leaders, pay and the cash
Who runs it
David Ricks has run Lilly since 2017 after a career there, and Daniel Skovronsky has run its research since 2018; the finance chief is the third since 2021. Insiders own almost none of the company. Most of the bonus rides on sales of newer drugs, profit per share and pipeline progress; the shares pay on the stock beating a cost of capital and rival drug makers. Nothing pays on cash or on the prices actually realised.
What they did with the money
It returned $4.0B through buybacks and $3.1B in dividends in the first half, while buying a string of small drug developers, the latest agreed on 31 August for up to $2.875B. Net debt was $45.96B at the end of June, about 1.6 times annualised profit.
The last report
The latest report
Lilly's sales rose 39% to $24.4B and it raised its forecast a third time
What it did to the thesis Strong quarter
It kept the strategy of trading price for volume working, and the forecast rose again. It did not touch what holds us at Neutral: one drug with a patent end date and a rival's pill. The slip in gross margin is the thing to watch next quarter.
The report
In the third quarter of 2026 sales rose 39% to $24.4B, on volume up 53% and prices down 15%. About $900M was one-off, mostly milestone payments from a partner. Foundayo, the new pill, sold $184M.
Profit per share rose 7% on the company's adjusted basis, held down by $4.57 a share of research bought in deals. Gross margin was 83.9%, a point up on a year ago but 1.9 points below the second quarter. The sales forecast rose to $91B to $92B; the earnings forecast edged down for the deals.
What's happening now
The background
The shares rose 50.4% in a year, yet buyers paid no more for each dollar of sales at the end than at the start: the rise was earned. They now sit 12.1% below their high.
The next test is the third-quarter report on 29 October: whether volume keeps outrunning the price cuts, and whether Lilly's share of new pill patients keeps climbing from 30%.
Where we disagree
Both sides in full
The market
Lilly has won obesity and is compounding into the largest medicine franchise ever built.
We believe
Right about the business, but too relaxed about a rival that won the pill market, and about coverage with an expiry date.
The argument
We read the rival's half-year report, not only its annual one, and that is where the fight shows. The market has twice sold these shares hard on one setback, a disappointing pill trial in August 2025 and CVS dropping Zepbound, and been wrong both times.
The evidence against us: two forecast raises, a heart-protection label in August, and a rival forecasting its own sales to shrink.
What it's worth
How we value it
Valued on the analysts' revenue path for three years, each later year closing 30% of the gap to 4%, on official operating profit with stock pay a cost and tax paid in full; the thesis's own evidence is the check on that path.
What the price assumes
Sales growth in the first year, then slowing as ours does, at the same profit per sale.
The price assumed
41.7%
Our estimate
40%
Measured at the close of
6 Nov 2026
The three cases
Bear case$433
Growth runs at half the analysts' path, 20%, 8% and 6%, the margin settles a fifth lower at 40.4%, and new capital earns only the 8% rate: the downturn test.
Our value$943
Revenue grows 40%, 17% and 12% over three years, the analysts' path (C71), then fades toward 4%, closing 30% of the gap each year; the margin moves to 50.5%, the analysts' year-three figure after stock pay.
Bull case$1,326
Growth runs a quarter above the analysts' path, 50%, 21% and 14%, the margin reaches 55.5%, and new capital earns 15%.
The bet
Seen as a bet
The bet is on Foundayo, Lilly's daily obesity pill, and retatrutide, a stronger injection not yet filed. Foundayo has sold for only one quarter and Novo's pill took the first year, so the rest of Lilly is counted separately, at thirty times this year's guided earnings.
If both medicines succeed, the shares are worth about what they cost today, because the price already pays for most of that. If they fail, shareholders keep about nine-tenths.
What could go wrong
Every risk
The risks
A generic challenge
Novo already faces a would-be generic of Ozempic. The same filing against tirzepatide would put the 2036 date itself in question.
Coverage with an end date
Medicare's Bridge programme covers 20 million Americans at $50 a month only until 31 December 2027.
Dearer than the disease
Obesity adds about $1,861 a year to an adult's medical bills; Lilly's cheapest stated price is $245 a month.
The efficacy gap narrowing
Novo's higher-dose Wegovy won European approval in July on up to 20.7% weight loss.
Copies and lawsuits
Unapproved copies are still sold, and Novo sued Lilly in July over its advertising.
What we still do not know
Whether Lilly's share of new American obesity-pill patients keeps climbing from the 30% it reached by mid-September.
Whether Medicare extends the Bridge programme past 2027, and on what price.
What changes our view
Every route to a new view
Every route to a new view
→ Neutral
The share price falls to about $1,131, back within 20% of what we think the business is worth.
→ Attractive
The share price falls to about $754, 80% of what we think the business is worth.
→ Attractive
Retatrutide, the next obesity drug, is filed on time in early 2027 and accepted, so a second molecule is really on the way. Volume keeps growing faster than prices fall, and Lilly keeps more than 20% of new American obesity-pill patients.
The next test
It supports the case if
Volume growth above 40% against a price decline no worse than the mid-teens, filed gross margin at or above 84%, Foundayo above 35% of new US oral patients, retatrutide's biologics application on schedule for the first quarter of 2027 - or any open-market purchase by an officer or director.
It pressures the case if
Volume growth below 30%, or a price decline steeper than 20%, or filed gross margin below 83%, or Foundayo's share of new oral patients flat to lower, or the retatrutide filing slipping.
We would also be wrong if
Volume growth falls below the price decline in any quarter.
Lilly's share of new American obesity-pill patients falls back below 20%.
The retatrutide filing slips, is withdrawn or is refused.
The verdict
Scores and how we weighed it
The scores
Growth
4 of 4
Business quality
3 of 4
Financial position
3 of 4
Execution record
4 of 4
Per share capture
4 of 4
Potential
3 of 4
Risk profile
3 of 4
Valuation
2 of 4
Evidence quality
4 of 4
How we weighed it
ValueNegative
The price sits above our value and above the bull case.
BusinessPositive
It leads the obesity-drug market with strong execution.
GrowthPositive
Sales grow very fast and the forecast rose again.
RisksNegative
A generic challenge looms, Medicare coverage ends on a date and one drug family carries most of it.
RivalsMixed
Mid-table on profit, but the dearest on sales and cash.
The groupMixed
It sits in none of our ranked groups; obesity-drug news moves it.
Latest newsPositive
The last report kept price-for-volume working and raised the forecast.
In plain words
Our estimate of value
We forecast how much cash the business can earn over the next ten years and beyond, then ask what that stream is worth today to an investor who wants an 8% yearly return. We do it three times: a gloomy future, an expected one and a sunny one. We call a share Attractive only when its price is at least 20% below the expected estimate, and Unattractive when it is 20% above.